Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Sep 23, 2023

Dr. Matthew Powell, professor of obstetrics and gynecology and Chief of the Gynecological Oncology Division at Washington University. He was also a clinical investigator in the pivotal trial leading to the approval of Jemperli, a treatment for endometrial cancer. This is an immunotherapy drug that works well for certain types of endometrial cancer and is now used in more than ten different cancers, decreasing the chance of the cancer progressing.

Matthew explains, "Some syndromes certainly can cause an increased risk of endometrial cancer. One was named after Dr. Henry Lynch, who first described it called Lynch syndrome, also known as hereditary non-polyposis colorectal cancer syndrome because the patients are not only at risk for endometrial cancer, but they're also at risk for colon cancer. So, we see a lot of families where there's both uterine and colon cancer in the family, and that's one where that genetic risk is there."

"When it came to therapies for patients who had disease that had spread, we, over the last 70 years, have been using radiation, which doesn't work very well. It treats the areas that we treat well, but we can't treat the whole body with radiation. So that's where chemotherapy came in. Chemotherapy has been a fairly standard therapy now for over 20 years. Still, we have not made many improvements over our standard treatment of what’s called carboplatin and paclitaxel, which, again, has been around since 1995. Over the last several decades, it’s become our standard treatment for this."

#EndometrialCancer #GSK #Jemperli #Immunotherapy #GynOnc

Listen to the podcast here